Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUDPatients ...
Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.
Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...
PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...
Brixadi (buprenorphine) is a prescription drug that’s used to treat opioid use disorder (OUD). Brixadi comes as a liquid solution in a prefilled syringe. You’ll receive Brixadi as an injection under ...
Sublocade (buprenorphine) is a brand-name subcutaneous injection prescribed for opioid use disorder. It works to help reduce the need for opioids by acting in certain areas of the brain called mu and ...
Indivior PLC, a revenue-generating company in the opioid dependence market, is trading near 52-week lows despite strong financials and solid prospects. The company faces competition, especially from ...
Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) These FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results